

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Delmotte

Group Art Unit

Application No.:

Examiner:

Filing Date: (Herewith)

For: Elongated Biopolymer Structure Containing Fibrin

Assistant Commissioner of Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure set forth under 37 CFR § 1.56, 1.97(b), and 1.98, Applicants enclose the attached form PTO-1449. The references listed are cited in the patent application filed herewith. Copies of the references are enclosed.

No fee is believed due; however, the Commissioner is authorized to charge any fees that may become due to **Deposit Account No. 02-1437 (WM252.00)**.

Respectfully submitted,

Baxter Healthcare Corporation
Post Office Box 15210
Irvine, CA 92623-5210

By

Janice Guthrie

Registration No. 35,170

Telephone: (949) 250-6828

CERTIFICATE OF MAILING

I hereby certify that the above-identified document, including all enclosures, is being deposited with the United States Postal Service as Express Mail, Label No. **EL524824204US** in an envelope addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on **March 6, 2001**.

By:

Mary Stickle
Mary Stickle